Somewhat Positive Press Coverage Somewhat Unlikely to Impact Nuvectra Corporation (NVTR) Stock Price

Headlines about Nuvectra Corporation (NASDAQ:NVTR) have trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Nuvectra Corporation earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.6877078342904 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of brokerages recently issued reports on NVTR. TheStreet raised shares of Nuvectra Corporation from a “d” rating to a “c-” rating in a research report on Monday, June 19th. Zacks Investment Research raised shares of Nuvectra Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Piper Jaffray Companies reissued a “neutral” rating and set a $14.00 price target on shares of Nuvectra Corporation in a research report on Thursday, July 6th. Finally, ValuEngine raised shares of Nuvectra Corporation from a “sell” rating to a “hold” rating in a research report on Friday, June 16th. Three equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $10.50.

Shares of Nuvectra Corporation (NASDAQ:NVTR) traded down 0.17% on Tuesday, reaching $12.10. 9,350 shares of the company were exchanged. The company’s 50-day moving average is $11.51 and its 200-day moving average is $10.91. The company’s market capitalization is $129.46 million. Nuvectra Corporation has a 52 week low of $4.63 and a 52 week high of $12.19.

Nuvectra Corporation (NASDAQ:NVTR) last issued its earnings results on Tuesday, August 8th. The company reported ($1.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.14) by $0.07. Nuvectra Corporation had a negative net margin of 232.31% and a negative return on equity of 56.68%. The company had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $5.96 million. During the same period in the prior year, the business earned ($0.85) EPS. The firm’s quarterly revenue was up 188.0% on a year-over-year basis. On average, equities analysts expect that Nuvectra Corporation will post ($4.77) EPS for the current fiscal year.

In other Nuvectra Corporation news, CEO Scott F. Drees bought 10,000 shares of the company’s stock in a transaction on Friday, August 11th. The shares were bought at an average cost of $11.72 per share, for a total transaction of $117,200.00. Following the acquisition, the chief executive officer now directly owns 125,180 shares in the company, valued at $1,467,109.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 3.60% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This report was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://sportsperspectives.com/2017/09/19/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-nuvectra-corporation-nvtr-stock-price.html.

Nuvectra Corporation Company Profile

Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.

Insider Buying and Selling by Quarter for Nuvectra Corporation (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply